HILDEN, Germany, and GERMANTOWN, Maryland, October 20, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced launch of QIAscout, a novel instrument for isolation of viable single cells from samples to enable cost-efficient, accurate single-cell analysis for next-generation sequencing (NGS), polymerase chain reaction (PCR) and other downstream applications. The QIAscout instrument, the size of a hand-held mobile device, adds to QIAGEN's Sample to Insight portfolio of solutions for single-cell analysis in research fields such as oncology, immunology, neurobiology and stem-cell biology.

"We continue to expand QIAGEN's Sample to Insight solutions to help researchers discover the processes underlying cellular function in both normal and disease states. Single-cell analysis is growing rapidly as NGS enables researchers to view biological processes at the highest level of resolution, including heterogeneity and changes in samples over time," said Brad Crutchfield, Senior Vice President of QIAGEN's Life Sciences Business Area. "QIAscout is a unique addition to QIAGEN's portfolio of sample technologies that provides an easy, fast and cost-effective method to isolate single cells from any sample. Other solutions are highly complex, expensive, and accessible only to large laboratories. In addition, they may stress the cells creating additional experimental variables. QIAscout, on the other hand, is powered by a novel approach to single cell isolation.

Click here [https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7b9C1ECF35-E9AA-43D6-B850-A2498A089C89%7d&lang=en ] for full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID= {9C1ECF35-E9AA-43D6-B850-A2498A089C89}&lang=en [https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7b9C1ECF35-E9AA-43D6-B850-A2498A089C89%7d&lang=en ]

ZEISS Microscopy / confocal microscopy / Dr. Lajos Kemeny / University of Szeged 


        
         
        Contacts 
        Public Relations: 
        Dr. Thomas Theuringer 
        Senior Director Public Relations 
        +49-2103-29-11826 

        Email: pr@qiagen.com 
        http://www.twitter.com/qiagen 
        https://www.facebook.com/QIAGEN 
        pr.qiagen.com [https://www.qiagen.com/de/about-us ]

         
        Investor Relations: 
        John Gilardi 
        Vice President Corporate Communications and Investor Relations 
        +49-2103-29-11711 

        Email: ir@qiagen.com 
        ir.qiagen.com [http://www.qiagen.com/About-Us/Investors ] 

 

SOURCE QIAGEN N.V.